Literature DB >> 24852395

MO06.12 Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): analyses based on age in the phase 3 PointBreak and E4599 trials.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24852395

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  5 in total

Review 1.  Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.

Authors:  Ryan D Gentzler; Sarah E Yentz; Jyoti D Patel
Journal:  Curr Treat Options Oncol       Date:  2013-12

2.  NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status.

Authors:  Grace K Dy; Julian R Molina; Yingwei Qi; Rafat Ansari; Sachdev Thomas; Helen J Ross; Gamini Soori; Daniel Anderson; Marie Christine Aubry; Jeffrey Meyers; Araba A Adjei; Sumithra Mandrekar; Alex A Adjei
Journal:  J Thorac Oncol       Date:  2014-08       Impact factor: 15.609

Review 3.  Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer.

Authors:  Ryan D Gentzler; Melissa L Johnson
Journal:  Oncologist       Date:  2015-02-06

4.  [Consensus of Chinese Experts on Medical Treatment of Advanced Lung Cancer 
in the Elderly (2022 Edition)].

Authors: 
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-06-20

5.  PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.

Authors:  Ralph G Zinner; Coleman K Obasaju; David R Spigel; Robert W Weaver; J Thaddeus Beck; David M Waterhouse; Manuel R Modiano; Borys Hrinczenko; Petros G Nikolinakos; Jingyi Liu; Andrew G Koustenis; Katherine B Winfree; Symantha A Melemed; Susan C Guba; Waldo I Ortuzar; Durisala Desaiah; Joseph A Treat; Ramaswamy Govindan; Helen J Ross
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.